1.Pediatric reference intervals for plasma and whole blood procalcitonin of in China: a multicenter research
Zhan MA ; Fangzhen WU ; Jiangtao MA ; Yunsheng CHEN ; Guixia LI ; Jinbo LIU ; Hongbing CHEN ; Huiming YE ; Xingyan BIAN ; Dapeng CHEN ; Jiangwei KE ; Haiou YANG ; Lijuan MA ; Qiuhui PAN ; Hongquan LUO ; Xushan CAI ; Yun XIE ; Wenqi SONG ; Lei ZHANG ; Hong ZHANG
Chinese Journal of Laboratory Medicine 2022;45(6):581-588
Objective:To establish the biology reference interval (RI) of peripheral blood procalcitonin (PCT) for children between 3 days and 6 years old in China.Methods:Totally 3 353 reference individuals with apparent health or no specific diseases were recruited in 18 hospitals throughout the country during October 2020 to May 2021. Reference individuals were divided into four groups: 3-28 days, 29 days - 1 year, 1-3 years and 4-6 years. Vein blood or capillary blood were collected by percutaneous puncture from every reference individual. The PCT level in serum and the capillary whole blood were assayed by Roche Cobas e601 and Norman NRM411-S7 immunoanalyzer. Outliers were deleted and 95th percentiles of every group were provided as RIs. Man-Whitney U test or Kruskal-Wallis test were used performed to assess the difference among different gender, age or method groups. Results:The difference of PCT distribution between male and female is not statistically significant, but the difference between serum and capillary whole blood is statistically significant. The differences between age groups are significant too. For Roche e601, serum PCT RI of 3-28 days group is <0.23 μg/L, 29 days - 6 years are <0.11 μg/L. For NRM411, Serum PCT RI of 3-28 days group is <0.21 μg/L, 29 days - 1 year: <0.09 μg/L, 1 - 6 years: <0.10 μg/L. For whole blood PCT, RI of 3-28 days group is <0.26 μg/L, 29 days - 6 years is <0.15 μg/L.Conclusions:Serum and capillary whole blood PCT have different RIs, however, capillary whole blood PCT testing is valuable in pediatric application. Children in 3-28 days show higher PCT levels than other age group. To establish the RIs and understand the differences among different groups are essential for the interpretation and clinical application of peripheral blood PCT testing results.
2.Research progress in the preoperative radiotherapy and immunotherapy for primary liver cancer
Wenhui LIU ; Xiaolian ZHENG ; Cairong HU ; Hongbing JI ; Jianji PAN ; Juhui CHEN
Chinese Journal of Radiological Medicine and Protection 2022;42(3):235-240
Liver cancer is one of the most common cancers in China. In recent years, liver cancer tends to be treated with comprehensive therapies, including surgery, ablation, interventional embolization, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and liver transplantation. At present, the low surgical resectionrate is one of the main factors affecting the prognosis of liver cancer patients. Preoperative neoadjuvant therapy or conversion therapy for liver cancer can maximize the rate of surgical resection and improve the prognosis. With the rapid development of radiotherapy and immunotherapy in the comprehensive treatment of liver cancer, it has been gradually confirmed that the unique effects of preoperative radiotherapy and immune therapy for liver cancer can improve the prognosis of the patients. Therefore, this paper reviewed the research progress in the preoperative radiotherapy and immunotherapy for liver cancer by searching relevant literature and reports at home and abroad.
3.Evaluation of the performance of systems for whole blood C-reactive protein detection: a multi-center study
Juan CHENG ; Huaiyuan LI ; Haipeng LIU ; Yuxin WANG ; Jin XU ; Shangyang SHE ; Wei QU ; Yidong WU ; Guixia LI ; Junmei YANG ; Liya MO ; Yun XIANG ; Jiangwei KE ; Liyue KUI ; Lei ZHENG ; Hongbing CHEN ; Zhili YANG ; Xin LYU ; Hong ZHANG ; Zhenhua TANG ; Lijuan MA ; Hongquan LUO ; Xiangyang LI ; Wenli ZHANG ; Hui JIA ; Huiming YE ; Lijun TIAN ; Qiuhui PAN
Chinese Journal of Laboratory Medicine 2021;44(7):633-643
Objective:To explore the performance of the commonly used whole blood C-reactive protein (CRP) detection systems and give related recommendation on the performance requirements of detection systems.Methods:A total of 7 540 venous blood samples from 26 maternal, child and children′s hospitals were collected to conduct this multi-center study on the analytical performance of 5 commonly used whole blood CRP detection systems from March to April in 2019. The blank check, carryover, repeatability, intermediate precision, linearity, sample stability, influence of hematocrit/triglyceride/bilirubin, comparison with SIEMENS specific protein analyzer and trueness were evaluated. The 5 systems included BC-5390CRP autohematology analyzer, AstepPLUS specific protein analyzer, Ottoman-1000 Automated Specific Protein POCT Workstation, i-CHROMA Immunofluorometer equipment Reader and Orion QuikRead go detecting instrument. The 5 systems were labeled as a, b, c, d and e randomly.Results:Within the 5 systems, all values of blank check were less than 1.00 mg/L, the carryovers were lower than 1.00%. The repeatability of different ranges of CRP concentrations including 3.00-10.00, 10.00-30.00 and>30.00 mg/L were less than 10.00%, 6.00% and 5.00%, respectively, and the intermediate precision was less than 10.00%. The linearity correlation coefficients of the 5 systems were all above 0.975, while the slope was within 0.950-1.050. Whole blood samples were stable within 72 hours both at room temperature (18-25 ℃) and refrigerated temperature (2-8 ℃). The CRP results were rarely influenced by high triglyceride or bilirubin, except for the immmunoturbidimetric test based on microparticles coated with anti-human CRP F(ab) 2 fragments. When triglyceride was less than 15.46 mmol/L, the deviation of CRP was less than 10.00%. When bilirubin was less than 345.47 μmol/L, the deviation of CRP was less than 10.00%. CRP was more susceptible to Hct on the systems without Hct correction. The deviation of CRP between different Hct dilution concentration and 40% dilution concentration can reach as high as 67.48%. The correlation coefficients ( r) of 5 systems were all more than 0.975 in the range of 0-300.00 mg/L compared with Siemens specific protein analyzer. All systems passed the trueness verification using the samples with specified values of 12.89 and 30.60 mg/L. Conclusion:The performance of 5 systems can basically meet the clinical needs, but it is suggested that the whole blood CRP detection system without automatic Hct correction should be modified manually.
4.The Role of Plasma CDO1 Methylation in the Early Diagnosis of Lung Cancer.
Pan WANG ; Honglin ZHAO ; Ruifeng SHI ; Xingyu LIU ; Jinghao LIU ; Fan REN ; Qingchun ZHAO ; Hongbing ZHANG ; Yongwen LI ; Hongyu LIU ; Jun CHEN
Chinese Journal of Lung Cancer 2020;23(5):314-320
BACKGROUND:
The incidence and mortality of lung cancer often rank first in all malignant tumors. DNA methylation, as one of epigenetics, often participates in the development and progression of tumors. CDO1 as a tumor suppressor gene always undergoes methylation changes early in tumor development. Therefore, this study aims to discuss the value of CDO1 methylation in the early diagnosis of lung cancer.
METHODS:
Peripheral blood samples were collected from tumor patients and healthy people. Detection of the methylation level of CDO1 in plasma by sulfite modification and quantitative real-time PCR.
RESULTS:
The level of gene methylation in peripheral blood of lung cancer patients was significantly higher than that of benign lung disease patients and healthy people. The methylation level of CDO1 was significantly different in the stratified comparison of gender, lymph node metastasis and tumor-node-metastasis (TNM) stage (P<0.05). The sensitivity and specificity of CDO1 were 52.2% and 78.6%, respectively. The overall accuracy of the diagnosis was significantly higher than that of the clinical tumor markers, and the sensitivity of CDO1 to stage I and II patients was the highest (40.8%, 47.1%). In addition, CDO1 could effectively increase the sensitivity of diagnosis in multiple joint examinations.
CONCLUSIONS
Detecting the methylation level of CDO1 has a potentially huge advantage for the early diagnosis of lung cancer.
5.Apatinib Combined with CCI-779 Inhibits the Proliferation and Migration of Small Cell Lung Cancer NCI-H446 Cells In Vitro.
Chao LIU ; Hongbing ZHANG ; Yongwen LI ; Zihe ZHANG ; Ruifeng SHI ; Songlin XU ; Guangsheng ZHU ; Pan WANG ; Hongyu LIU ; Jun CHEN
Chinese Journal of Lung Cancer 2020;23(4):216-222
BACKGROUND:
Lung cancer is the most common malignancy world-wide. Small cell lung cancer is the deadliest subtype of lung cancer, which features such as rapid growth, early metastasis, and high vascularization. Apatinib is a vascular endothelial growth factor receptor 2 inhibitor independently developed in China, which has a significant inhibition in a variety of solid tumors. The purpose of this study is to investigate the effects of Apatinib alone or Apatinib combined with mammalian target of rapamycin (mTOR) inhibitor, CCI-779, on small cell lung cancer cell line NCI-H446 in vitro.
METHODS:
The small cell lung cancer cell line NCI-H446 was grew in vitro. The effects of Apatinib alone or Apatinib combined with CCI-779 on proliferation, apoptosis, cell cycle and migration of NCI-H446 small cell lung cancer cells were detected by CCK8; FACS and transwell assays were also carried out; Western blot assays were used to detect vascular endothelial growth factor and cell cycle related protein expression.
RESULTS:
CCK8 assays showed that high concentration of Apatinib could inhibit the proliferation of NCI-H446 cells. Apoptosis assays showed that high concentration of Apatinib could induce NCI-H446 cell apoptosis. Transwell assays showed that high concentration of Apatinib could inhibit NCI-H446 cell migration. After combined with mTOR inhibitor CCI-779, low concentration of Apatinib could inhibit the proliferation and migration of NCI-H446 small cell lung cancer cells and induce apoptosis.
CONCLUSIONS
Apatinib has a concentration-dependent effect on the small cell lung cancer cell line NCI-H446. High concentration of Apatinib can inhibit the proliferation and migration of NCI-H446 small cell lung cancer cells, induce apoptosis. Apatinib combined with the mTOR inhibitor CCI-779 can sensitize the NCI-H446 cells to Apatinib.
6.In vitro expression of sodium taurocholate cotransporting polypeptide in bone marrow mesenchymal stem cells and its role during HBV infection
Meijuan WEI ; Sican WEI ; Xingnan PAN ; Hongbing DING ; Yuxia CHEN ; Queling REN
Chinese Journal of Microbiology and Immunology 2020;40(11):832-837
Objective:To investigate whether in vitro cultured human bone marrow mesenchymal stem cells (BMSCs) express sodium taurocholate cotransporting polypeptide (NTCP), assess their susceptibility to hepatitis B virus (HBV) infection and analyze the role of NTCP during HBV infection. Methods:BMSCs were infected with HBV-positive serum under different conditions. HBV DNA load in cell culture supernatants as well as in BMSCs and the amount of hepatitis B virus surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg) in cell culture supernatants were detected. To analyze the role of NTCP, BMSCs were first transfected with small interfering RNA targeting NTCP (NTCP-siRNA) and then infected with HBV-positive serum under different conditions. Virus loads and the amount of HBsAg and HBsAg were also detected. Western blot assay was performed to measure the expression of NTCP in BMSCs in each group.Results:In vitro cultured adherent BMSCs were susceptible to HBV infection albeit with a really low efficiency, but the infection efficiency was significantly increased when infecting the BMSCs in suspension. NTCP was expressed in BMSCs and the expression could be upregulated during HBV infection, especially in BMSCs in suspension. HBV infection was blocked when BMSCs were transfected with NTCP-siRNA. Conclusions:In vitro cultured human BMSCs were susceptible to HBV infection and the expressed NTCP served as a functional receptor for HBV. Human BMSCs could be used as a highly susceptible and stable cell model that needed no molecular adjuvant modification for research on the early stages of the HBV life cycle and for development of antiviral therapy.
7. Study on the effect of occupational exposure to glyphosate on blood routine
Feng ZHANG ; Hongbing ZHANG ; Liping PAN ; Xin LIU ; Jianrui DOU ; Baoli ZHU
Chinese Journal of Industrial Hygiene and Occupational Diseases 2019;37(2):126-129
Objective:
To investigate the effect of glyphosate on blood routine of occupational exposure population.
Methods:
The workers who were occupationally exposed to glyphosate were selected as exposure group, and administrative staffs who were not exposed to glyphosate were selected as control group. Occupational health examination was conducted on all the subjects, and personal monitoring was applied to detect the concentration of glyphosate in the air of workplace. Time weighted average (TWA) concentration was calculated by the result of determination. Statistical methods were employed to compare the difference of blood routine results between the contact group and the control group, as well as between different posts.
Results:
178 glyphosate workers were included in the contact group, and 203 non-contact persons were included in the control group. There was no statistically significant difference in the equilibrium test between the two groups(
8.Effect of Apatinib on Invasion and Migration of Lung Cancer Cells and Its Mechanism.
Yin YUAN ; Hao GONG ; Yongwen LI ; Hongbing ZHANG ; Ying LI ; Weiting LI ; Pan WANG ; Ruifeng SHI ; Hongyu LIU ; Jun CHEN
Chinese Journal of Lung Cancer 2019;22(5):264-270
BACKGROUND:
Lung cancer is one of the most deadly cancers in the world for human. In recent years, the effect of targeted therapy has become increasingly significant. Apatinib is a multi-target anti-tumor drug that is currently under study. The purpose of this study is to investigate the effects of Apatinib on the biological characteristics of lung cancer cells and its possible mechanism.
METHODS:
Lung cancer cell lines H1299 and H3255 were cultured in vitro. The effects of Apatinib on proliferation, migration and invasion of H1299 and H3255 cells were detected by cell proliferation assays wound healing assays and Transwell assays. The protein expression related to cancer angiogenesis and invasion was detected by Western blot.
RESULTS:
Apatinib significantly inhibited the proliferation, migration and invasion of H1299 and H3255 in a concentration-dependent manner. Western blot showed that with the increasing of drug concentration, VEGF, VEGFR2, N-cadherin, MMP9, MMP2 and Vimentin were down-regulated, and E-cadherin were up-regulated.
CONCLUSIONS
Apatinib can inhibit the invasion and migration of lung adenocarcinoma cells H1299 and H3255. By regulation of epithelial-mesenchymal transition and the expression of matrix metalloproteinase-related proteins.
Antineoplastic Agents
;
pharmacology
;
Cell Line, Tumor
;
Cell Movement
;
drug effects
;
Humans
;
Lung Neoplasms
;
pathology
;
Neoplasm Invasiveness
;
Pyridines
;
pharmacology
9.Role of EZH2 Inhibitor Combined with Gefitinib in EGFR-TKIs Resistant Lung Cancer Cells.
Hao GONG ; Yin YUAN ; Yongwen LI ; Hongbing ZHANG ; Ying LI ; Weiting LI ; Pan WANG ; Ruifeng SHI ; Chao LIU ; Liyuan CUI ; Hongyu LIU ; Jun CHEN
Chinese Journal of Lung Cancer 2019;22(5):255-263
BACKGROUND:
Lung cancer is one of the common malignant tumors that impair human health. With the development of epigenetics, the researchers found that enhancer of Zeste homolog 2 (EZH2) is highly expressed in lung cancer tissue and its expression is closely related to the prognosis. EZH2 inhibitor can also enhance the sensitivity of tumor cells to a variety of anti-tumor drugs. The purpose of this study is to investigate the effect of combination of EZH2 inhibitor and gefitinib on the proliferation, apoptosis and migration of Gefitinib-resistant lung cancer cells.
METHODS:
PC9 and PC9/AB2 cells were used for this study. CCK-8 and EdU experiment were used to detect combined treatment on cell viability and proliferation activity; Wound healing assay and Transwell chamber experiment were used to determine the effects of combination therapy on cell migration ability; Flow cytometry was used to detect the effect of combination therapy on EZH2 and apoptosis; Western blot was used to observe the effect of combination therapy on epidermal growth factor receptor (EGFR) signaling pathway-related proteins expression.
RESULTS:
In gefitinib-resistant cell line PC9/AB2, gefitinib combined with EZH2 inhibitor GSK343 can significantly inhibit cell viability, reduce cell migration and increase cell apoptosis. At the same time, combination therapy can significantly inhibit the expression of EZH2 and phosphorylation EGFR proteins.
CONCLUSIONS
The combination of EZH2 inhibitor GSK343 and gefitinib sensitize PC9/AB2 cell to gefitinib response. This study also suggests that synergistic therapy plays a role in the reversal of EGFR-tyrosine kinase inhibitor (EGFR-TKIs) resistance in lung cancer.
Antineoplastic Agents
;
pharmacology
;
Cell Line, Tumor
;
Cell Movement
;
drug effects
;
Cell Proliferation
;
drug effects
;
Cell Survival
;
drug effects
;
Drug Resistance, Neoplasm
;
drug effects
;
Drug Synergism
;
Enhancer of Zeste Homolog 2 Protein
;
antagonists & inhibitors
;
ErbB Receptors
;
antagonists & inhibitors
;
Gefitinib
;
pharmacology
;
Humans
;
Lung Neoplasms
;
pathology
;
Protein Kinase Inhibitors
;
pharmacology
10.Comparative Analysis of Volatile Oil Constituents of Glehnia littoralis from Different Producing Areas
Huiming WANG ; Zhiqiang LYU ; Hao’er ZHANG ; Dongqi PAN ; Pengrui WANG ; Hongbing LIU
China Pharmacy 2019;30(22):3109-3112
OBJECTIVE: To compare the difference in volatile oil constituents of Glehniae littoralis from 3 producing areas as Shandong Laiyang, Hebei Anguo, Inner Mongolian Chifeng. METHODS: The method of steam distillation was used to extract the volatile oil of G. littoralis from different areas and calculate the extraction rate. The constituents of volatile oil were analyzed by using GC-MS. The data was corrected by Xcalibur chemical workstation. The constituents were searched by NIST 11.0 mass spectrometry database (matching degree >800), and the relative mass fraction of each chemical constituent was obtained by peak area normalization. RESULTS: The extraction rate of volatile oil in G. littoralis from Laiyang was 0.013%, which was far lower than G. littoralis from Anguo (0.099%) and G. littoralis from Chifeng (0.105%). There were 15, 18 and 27 constituents identified in volatile oil of G. littoralis from 3 producing areas; the relative mass fractions were 89.29%, 96.76%, 94.53%. Falcarinol was a common compound with the highest relative mass fraction of the volatile oil of G. littoralis from different producing areas; the relative mass fractions were 69.79%, 90.89% and 71.04%, respectively. Fatty acids were rich in the sample from Laiyang, while C15H24 sesquiterpenoids were rich in the other samples from Anguo and Chifeng. CONCLUSIONS: Volatile oil of G. littoralis could be used as potential chemical markers to distinguish different producing areas due to their significant differences in chemical components.

Result Analysis
Print
Save
E-mail